Brief: UK's MHRA Completes Review Of Avacopan Vifor
01/09/2026 13:29
BRIEF-UK's MHRA Completes Review Of Avacopan Vifor Sept 1 (Reuters) - UK'S MHRA:
UK'S MHRA: COMPLETED REVIEW OF AVACOPAN VIFOR, FOUND THAT AVAILABLE EVIDENCE NO LONGER SUPPORTS POSITIVE BENEFIT-RISK BALANCE FOR MEDICINE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally